Publications
192
Citations
1,811
Est. group size
~66
Recurring co-author estimate
Active years
19
Publishing since 2008
Adam S. Kittai's research focuses on blood cancers, particularly chronic lymphocytic leukemia (CLL), lymphoma, and Richter's transformation (a rare and aggressive change of CLL into a more severe lymphoma). His work includes clinical trials testing new drug combinations, comparisons of existing therapies, and studies of real-world treatment outcomes and disparities in access to care, especially by race and ethnicity.
Publication output grew substantially from 2017 through 2023, peaking at 40 papers, and has remained high (around 25-27 per year) in 2024-2025, suggesting a strong and sustained level of research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Mediators of racial and ethnic inequities in access to front-line therapies for chronic lymphocytic leukemia in the United States: A real-world evidence study
Blood · 2025
- Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States
Blood · 2025
- Real-world outcomes of younger patients with chronic lymphocytic leukemia treated with first-line BTK inhibitor or BCL2 inhibitor therapy
Blood · 2025
- Consolidation (Cons) and maintenance (Maint) approaches in primary central nervous system lymphoma (PCNSL) after high-dose methotrexate induction in transplant-ineligible patients
Blood · 2025
- SOHO State of the Art Updates and Next Questions | Richter Transformation in the Modern Era of Therapy
Clinical Lymphoma Myeloma & Leukemia · 2025
- 208 | COMPARATIVE EFFICACY OF IBRUTINIB VERSUS OTHER COVALENT BRUTON TYROSINE KINASE INHIBITORS IN FIRST‐LINE CHRONIC LYMPHOCYTIC LEUKEMIA: A MATCHED‐ADJUSTED INDIRECT COMPARISON
Hematological Oncology · 2025
- Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
The Lancet · 2025
- Safety and efficacyof the combination of copanlisib and nivolumab in patients with Richter’s transformation or transformed non-Hodgkin lymphoma: results from a phase I trial
Haematologica · 2025
- Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia
Journal of Comparative Effectiveness Research · 2025
- Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.
Blood · 2025
- Long-term follow up of nivolumab/ipilimumab-primed immunotransplant in patients with Relapsed/Refractory DLBCL
Blood · 2025
- Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology · 2025
- Comparative efficacy of ibrutinib versus other covalent Bruton tyrosine kinase inhibitors (cBTKis) in first-line (1L) chronic lymphocytic leukemia (CLL): A matched-adjusted indirect comparison (MAIC).
Journal of Clinical Oncology · 2025
- 557 | EVALUATING UPTAKE OF TARGETED AGENTS BY RACE/ETHNICITY IN PATIENTS RECEIVING FIRST‐LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA
Hematological Oncology · 2025
- An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL
Blood Advances · 2024
- Blood×64
- Journal of Clinical Oncology×14
- Blood Advances×12
- Leukemia×8
- Haematologica×5
- Farrukh T. Awan
Medicine · The Ohio State University
- Seema A. Bhat
Medicine · The Ohio State University
- Samantha Jaglowski
Medicine · The Ohio State University
- Max Yano
Medicine · The Ohio State University
- Jennifer A. Woyach
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile